NYSE · RMD
Healthcare · Medical - Instruments & Supplies
$230.05
Up+$3.32 (+1.46%)
Updated Oct 10, 2026, 5:11 PM
SID Score
6.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance · RMD
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
RMD closed at $230.05 after 21 trading sessions, up 5.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $226.54 | $231.36 | $226.415 | $230.05 | 1M |
| Oct 8, 2026 | $225.79 | $226.875 | $223.04 | $226.73 | 651.15K |
| Oct 7, 2026 | $222.27 | $228.75 | $221.83 | $225.98 | 1.13M |
| Oct 6, 2026 | $223.90 | $225.23 | $219.96 | $220.69 | 972.85K |
| Oct 5, 2026 | $218.44 | $223.72 | $218.44 | $222.86 | 976.46K |
| Oct 2, 2026 | $221.66 | $223.73 | $218.03 | $218.89 | 898.89K |
| Oct 1, 2026 | $220.75 | $224.135 | $219.00 | $221.15 | 930.42K |
| Sep 30, 2026 | $222.63 | $224.04 | $220.00 | $221.10 | 1.31M |
| Sep 29, 2026 | $221.96 | $224.22 | $220.32 | $222.83 | 949.4K |
| Sep 28, 2026 | $221.52 | $223.00 | $218.26 | $222.10 | 862.83K |
| Sep 25, 2026 | $221.08 | $223.215 | $220.13 | $222.00 | 760.79K |
| Sep 24, 2026 | $223.08 | $224.50 | $220.385 | $221.89 | 798.77K |
| Sep 23, 2026 | $222.78 | $225.095 | $220.00 | $222.30 | 1.44M |
| Sep 22, 2026 | $226.22 | $227.90 | $221.82 | $221.97 | 1.03M |
| Sep 21, 2026 | $225.16 | $226.52 | $223.34 | $223.61 | 1.07M |
| Sep 18, 2026 | $228.21 | $228.385 | $224.56 | $224.99 | 3.86M |
| Sep 17, 2026 | $228.25 | $229.57 | $225.08 | $228.42 | 1.09M |
| Sep 16, 2026 | $228.19 | $229.325 | $224.26 | $228.25 | 1.07M |
| Sep 15, 2026 | $226.36 | $234.33 | $225.115 | $229.44 | 1.64M |
| Sep 14, 2026 | $221.04 | $225.82 | $220.94 | $222.99 | 989.01K |
| Sep 11, 2026 | $220.44 | $221.29 | $215.97 | $218.27 | 912.33K |
The latest Smart Investors Daily articles mentioning RMD.
Company
Market Activity
Research & News
RMD research
Company profile and research snapshot.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | RBC Capital | Outperform | — |
| Aug 31, 2026 | Keybanc | Overweight | — |
| Aug 19, 2026 | Rothschild & Co | Neutral | — |
| Aug 7, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 7, 2026 | Keybanc | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 2, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Yahoo · Oct 1, 2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: https://investor.resmed.comDate
Yahoo · Sep 28, 2026
Glucose monitoring company DexCom’s investment in Oura values the company at just over $5 billion. Oura is looking to go public at a valuation above $15 billion.
Yahoo · Sep 21, 2026
ResMed (NYSE:RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care. Chairman and Chief Executive Officer Mick Farrell sai
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RMD.
